Several steps occur between the reaction of a chemical with DNA and a mutation, and each may influence the resulting mutation spectrum, i.e. nucleotides at which the mutations occur. The half-mustard S-(2-bromoethyl)glutathione is the reactive conjugate implicated in ethylene dibromide-induced mutagenesis attributed to the glutathione-dependent pathway. A human p53-driven Ade reporter system in yeast was used to study the factors involved in producing mutations. The synthetic analog S-(2-chloroethyl)glutathione was used to produce DNA damage; the damage to the p53 exons was analyzed using a new fluorescence-based modification of ligation-mediated polymerase chain reaction and an automated sequencer. The mutation spectrum was strongly dominated by the G to A transition mutations seen in other organisms with S-(2-chloroethyl)glutathione or ethylene dibromide. The mutation spectrum clearly differed from the spontaneous spectrum or that derived from N-ethyl,N-nitrosourea. Distinct differences were seen between patterns of modification of p53 DNA exposed to the mutagen in vitro versus in vivo. In the four p53 exons in which mutants were analyzed, the major sites of mutation matched the sites with long half-lives of repair much better than the sites of initial damage. However, not all slowly repaired sites yielded mutations in part because of the lack of effect of mutations on phenotype. We conclude that the rate of DNA repair at individual nucleotides is a major factor in influencing the mutation spectra in this system. The results are consistent with a role of N 7 -guanyl adducts in mutagenesis.The somatic theory of cancer holds that carcinogens are mutagens, at least with regard to what are classically termed tumor initiators (1-3). In a general model, cells are initiated by damage resulting from a DNA-alkylating agent, yielding mutations that are fixed by subsequent rounds of replication. Mutation spectra are generally observed when chemical damage to the DNA occurs; i.e. the sites of the mutation are not random and are often characteristic of the DNA-damaging agent (4, 5). Sometimes mutant spectra can be measured in tumors (in experimental animals or humans), although the existence of any "hotspots" for mutations does not necessarily indicate that the particular mutation is the cause of the tumor. The biochemical basis for where mutations occur (i.e. the mutant spectrum) is generally not well understood. Mutation resulting from chemical damage to DNA is a multistep process, and the observed mutant spectrum may be the result of events occurring during five or possibly more individual processes: (i) reaction of the chemical with DNA, (ii) further non-enzymatic reactions of the DNA adduct (e.g. opening of the imidazole ring in the case of guanyl-N 7 alkyl adducts), (iii) DNA repair (or, more specifically, resistance to repair), (iv) the action of DNA polymerases, and (v) the biological effect of a particular nucleotide/amino acid change in the phenotypic assay used.Ethylene dibromide (1,2-dibromoethane, BrCH 2 CH 2 ...